Company / PP&E (Net)
NovaBay Pharmaceuticals, Inc. PP&E (Net) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$53.0K
FY2024
5-year range
$53.0K / $193.0K
FY2020-FY2024
Trend
-39.1%
vs FY2023
Sector context
#190 of 195
Health Care
What the data says
Among 195 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the bottom 3% for pp&e (net). PP&E (Net) has declined for 3 consecutive years, from $193,000 in FY2021 to $53,000 in FY2024.
Based on SEC 10-K filings.
$53,000 in FY2024 with a 5-year CAGR of -13.6%.
Declined from $119,000 to $53,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -35.0%
- 5-Year CAGR
- -13.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 195This company $53.0K Sector average $770.1M
▼
-100.0% below sector average
Key checks
Key Insights
- NovaBay Pharmaceuticals, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of -13.6%, indicating a declining trend.
- In FY2024, pp&e (net) decreased 39.1% year-over-year.
- Ranks #190 out of 195 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $53.0K | -39.1% |
| FY2023 | $87.0K | -26.9% |
| FY2022 | $119.0K | -38.3% |
| FY2021 | $193.0K | +129.8% |
| FY2020 | $84.0K | -23.6% |
| FY2019 | $110.0K | -45.3% |
| FY2018 | $201.0K | -57.3% |
| FY2017 | $471.0K | +27.0% |
| FY2016 | $371.0K | -6.1% |
| FY2015 | $395.0K | -9.4% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026